On Thursday, Shares of Alibaba Group Holding Ltd (NYSE:BABA), gain 3.09% to $70.78, as some China-based U.S. traded stocks are lower amid the country’s economic downturn.
The Shanghai Composite Index closed down 1.3% recently, marking its fifth successive day of losses as China contends with an economic slowdown that is affecting global markets.
The country’s economy has struggled to rebound from its central bank’s unpredictable devaluation of the yuan two weeks ago, and investors were largely unmoved by its attempts to stimulate growth yesterday with cuts to interest rates and banks’ reserve requirements, The Wall Street Journal reports.
Although China’s economic woes have been “treacherous” for China-based holding company Alibaba and similar stocks, the country’s cross-border initiatives should benefit from the currency devaluation and investors should continue to buy the stock, MKM said after concluding a proprietary survey of Chinese consumers, according to Barron’s.
The stock completed the day with a total volume of 18.12M shares, versus an average volume of 14.99M shares. The share price hit its 52-week low of $58.00 on Aug 24, 2015 and $120.00 was the best price in the same period.
Alibaba Group Holding Limited, through its auxiliaries, operates as an online and mobile commerce company in the People’s Republic of China and internationally. It operates Taobao Marketplace, an online shopping destination; Tmall, a third-party platform for brands and retailers; Juhuasuan, a group buying marketplace; Alibaba.com, an online wholesale marketplace; Alitrip, an online travel booking platform; 1688.com, an online wholesale marketplace; and AliExpress, a consumer marketplace.
Shares of Mylan NV (NASDAQ:MYL), inclined 0.70% to $51.49, during its last trading session.
Mylan NV, declared that the U.S. Patent and Trademark Office (PTO) has instituted inter partes review (IPR) proceedings against two Copaxone® 40 mg/mL patents, U.S. Patent Nos. 8,232,250 and 8,399,413, owned by Yeda Research & Development Co., Ltd. and licensed to Teva Pharmaceuticals Industries Ltd. The patents relate to methods for the treatment of multiple sclerosis through the administration of at least three 40 mg subcutaneous injections of glatiramer acetate over a period of seven days with at least one day between each injection. Mylan also has filed another petition for inter partes review of a related patent (U.S. Patent No. 8,969,302), which the PTO is predictable to act upon shortly.
Mylan CEO Heather Bresch commented, “We believe that the patents at question are invalid and are happy that, in instituting an inter partes review on all claims, the PTO has determined that there is a reasonable likelihood of prevailing on the invalidity assertion. We believe our generic version of Copaxone 40mg/mL represents an exciting first-to-file opportunity for Mylan.”
Mylan N.V., through its auxiliaries, develops, licenses, manufactures, markets, and distributes generic, branded generic, and specialty pharmaceuticals worldwide. The company provides generic or branded generic pharmaceutical products in tablet, capsule, injectable, or transdermal patch forms, in addition to active pharmaceutical ingredients (APIs).
Finally, Westlake Chemical Corporation (NYSE:WLK), ended its last trade with 3.84% gain, and closed at $54.62.
The Board of Directors of Westlake Chemical Corporation (WLK) declared on Friday, August 21, 2015, a dividend of $0.1815 per share, an enhance of 10% from the $0.165 per share paid in the second quarter of 2015. The dividend will be payable on September 22, 2015, to stockholders of record on September 4, 2015.
Westlake Chemical Corporation manufactures and markets basic chemicals, vinyls, polymers, and fabricated building products. It operates through two segments, Olefins and Vinyls. The Olefins segment offers ethylene, polyethylene, styrene monomer, and various ethylene co-products, such as chemical grade propylene, crude butadiene, pyrolysis gasoline, and hydrogen.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
